Differential (Click to cross reference) antihistamines clemastine fumarate efficacy evoked potentials multiple sclerosis multiple sclerosis, chronic progressive multiple sclerosis, treatment of ReBUILD study remyelination safety treatment of neurologic disorder visual evoked response

Showing articles 0 to 7 of 7 Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial Lancet 390:2481-2489, Green, A.J.,et al, 2017 Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis NEJM 367:1098-1106,1149, Gold, R.,et al, 2012 Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012 Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study Lancet 372:1463-1472, Kappos,L.,et al, 2008 Showing articles 0 to 7 of 7